Pharmaceuticals
-
Hope for simple sleeping sickness treatment
A new ‘simple’ approach to treating sleeping sickness appears to be highly effective, researchers report today. Read more
-
Pandemic experience used to find flu treatments
A £2.9 million national trial, launched today to help find effective treatments for people hospitalised with severe flu, will replicate lessons learnt in the pandemic. Read more
-
Precision medicine tested for rare cancers
A major new trial of precision medicine will seek treatments for patients with rare cancers, it has been announced. Read more
-
Protein discovery could lead to less toxic cancer drugs
Better, less toxic cancer drugs could be developed following the discovery into how a key protein involved in a wide range of cellular processes works, British scientists have reported. Read more
-
COVID vaccine still ‘worthwhile’ in previously infected
New research adds to evidence that people who have been infected with COVID-19 and developed antibodies still benefit from vaccination. Read more
-
Alarm as survey shows widespread use of unprescribed antibiotics
The majority of antibiotics in parts of eastern Europe may be circulating without prescriptions, according to an alarming new investigation. Read more
-
Alarm as drug resistant malaria emerges
Parasites have emerged that are resistant to malaria drugs, posing a threat to thousands around the world, the World Health Organization has warned. Read more
-
New drug could ‘slow neurodegenerative disease’
A novel drug has been shown to slow the progression of neurodegenerative disease in mice, giving hope for those investigating treatments for conditions such as Alzheimer’s disease. Read more
-
Hope for lung cancer halting protein
A protein is linked to mortality risk for lung cancer patients and might be a therapeutic target, according to a new study. Read more
-
Immune cells reprogrammed to destroy cancer
British scientists are working on a novel technique to reduce the support given by the immune system to growing cancer cells. Read more
